

# AMG 487

**Catalog No: tcsc2662**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

473719-41-4

**Formula:**

$C_{32}H_{28}F_3N_5O_4$

**Pathway:**

GPCR/G Protein;Immunology/Inflammation

**Target:**

CXCR;CXCR

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 41$  mg/mL (67.93 mM)

**Observed Molecular Weight:**

603.59

## Product Description


AMG 487 is an antagonist of the chemokine receptor **CXCR3**, which inhibits binding of  $^{125}I$ -IP-10 and  $^{125}I$ -ITAC to CXCR3 with **IC<sub>50</sub>**

values of 8.0 and 8.2 nM, respectively.

IC<sub>50</sub> & Target: IC<sub>50</sub>: 8.0 nM (<sup>125</sup>I-IP-10 binding to CXCR3), 8.2 nM (<sup>125</sup>I-ITAC binding to CXCR3)

**In Vitro:** AMG 487 inhibits CXCR3-mediated cell migration by the three CXCR3 chemokines (IP-10 IC<sub>50</sub>=8 nM, ITAC IC<sub>50</sub>=15 nM, and MIG IC<sub>50</sub>=36 nM). Furthermore, AMG 487 inhibits calcium mobilization in response to ITAC (IC<sub>50</sub>=5 nM)<sup>[1]</sup>. AMG487 (1 μM) develops into fewer lung metastases, and the lungs are significantly smaller than vehicle-treated lungs<sup>[2]</sup>. AMG487 abrogates proliferation/survival of C26 tumour cells<sup>[3]</sup>.

**In Vivo:** AMG 487 (0.03-10 mg/kg, s.c.) exhibits significant reduction in cellular infiltration into the lungs in a dose dependent manner<sup>[1]</sup>. AMG487 (5 mg/kg, s.c., twice daily) develops fewer metastases than that in vehicle-treated mice<sup>[2]</sup>. AMG487 (5 mg/kg, s.c.)-treated mice exhibits fewer pulmonary nodules than the control mice in both the models. AMG487 reduces the tumour volume<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!